دواعي استعمال تازوسين 4.5 جم فيال 4 جم / 0.5 جم

Piperacillin 4 g / tazobactam 0.5 g powder for solution for intravenous infusion, single vial (Pfizer); broad-spectrum penicillin with beta-lactamase inhibitor.

• Severe pneumonia including hospital-acquired and ventilator-associated pneumonia (adults/adolescents)patient-info.co.uk (MHRA SmPC text)
• Complicated urinary tract infections including pyelonephritis (adults/adolescents)patient-info.co.uk (MHRA SmPC text)
• Complicated intra-abdominal infections (adults, adolescents and children 2-12 years)patient-info.co.uk (MHRA SmPC text)
• Complicated skin and soft tissue infections including diabetic foot infections (adults/adolescents)patient-info.co.uk (MHRA SmPC text)
• Bacteraemia associated with the above infectionspatient-info.co.uk (MHRA SmPC text)
• Febrile neutropenia suspected to be bacterial (adults and children)patient-info.co.uk (MHRA SmPC text)

• Very common: diarrhoea. Common: candida infection, thrombocytopenia, anaemia, insomnia, headache, abdominal pain, vomiting, constipation, nausea, dyspepsia, rash, pruritus, raised transaminases, pyrexia, injection-site reaction.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)

• Hypersensitivity to piperacillin, tazobactam, any other penicillin or excipients.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)
• History of acute severe allergic reaction to other beta-lactams (cephalosporin, monobactam, carbapenem).نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)

• Serious, occasionally fatal hypersensitivity reactions; Kounis syndrome reported.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)
• Severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP).نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)
• Haemophagocytic lymphohistiocytosis, rhabdomyolysis, pseudomembranous colitis, bleeding, leukopenia/neutropenia, seizures at high doses in renal impairment.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)
• Each 4 g/0.5 g vial contains 261 mg sodium; hypokalaemia possible; nephrotoxicity and increased AKI with vancomycin.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)

• Non-depolarising muscle relaxants (e.g. vecuronium)Neuromuscular blockade may be prolonged.patient-info.co.uk (MHRA SmPC text)
• Anticoagulants (heparin, oral anticoagulants)Monitor coagulation tests more frequently.patient-info.co.uk (MHRA SmPC text)
• MethotrexatePiperacillin may reduce methotrexate excretion; monitor levels.patient-info.co.uk (MHRA SmPC text)
• ProbenecidLonger half-life and lower renal clearance of both components.patient-info.co.uk (MHRA SmPC text)
• Aminoglycosides (tobramycin, gentamicin)In vitro inactivation; administer separately.patient-info.co.uk (MHRA SmPC text)
• VancomycinIncreased incidence of acute kidney injury.patient-info.co.uk (MHRA SmPC text)

• Limited data; both components cross the placenta; use only if clearly indicated.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)
• Piperacillin is excreted in low concentrations in human milk; treat only if expected benefit outweighs risks.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)

• Periodic haematopoietic function during prolonged therapy; electrolytes in patients at risk of hypokalaemia; renal function; coagulation tests with anticoagulants; methotrexate levels if co-administered.نشرة دولية لنفس المنتج · patient-info.co.uk (MHRA SmPC text)

• Bactericidal; inhibits bacterial septum and cell-wall synthesis (UK SmPC 5.1).
• Inhibits many beta-lactamases (not AmpC or metallo-beta-lactamases), extending piperacillin spectrum (UK SmPC 5.1).